tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating for Spyre Therapeutics: Promising AFFINITY Study Results in Autoimmune Disease Market
PremiumRatingsBuy Rating for Spyre Therapeutics: Promising AFFINITY Study Results in Autoimmune Disease Market
2M ago
Promising Potential of Spyre Therapeutics’ Innovative IBD Treatments Earns Buy Rating
Premium
Ratings
Promising Potential of Spyre Therapeutics’ Innovative IBD Treatments Earns Buy Rating
2M ago
Spyre Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Spyre Therapeutics Reports Q2 2025 Financial Results
2M ago
Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
PremiumRatingsPromising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
4M ago
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
Premium
Ratings
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
4M ago
Spyre Therapeutics Announces Positive Phase 1 Results
Premium
Company Announcements
Spyre Therapeutics Announces Positive Phase 1 Results
4M ago
Spyre Therapeutics: Promising Developments in IBD Treatment with Biologics-Based Therapies
PremiumRatingsSpyre Therapeutics: Promising Developments in IBD Treatment with Biologics-Based Therapies
5M ago
Promising Outlook for Spyre Therapeutics: Buy Rating Backed by Strong Financials and Positive Clinical Progress
Premium
Ratings
Promising Outlook for Spyre Therapeutics: Buy Rating Backed by Strong Financials and Positive Clinical Progress
5M ago
Promising Potential and Strategic Advancements Justify Buy Rating for Spyre Therapeutics
Premium
Ratings
Promising Potential and Strategic Advancements Justify Buy Rating for Spyre Therapeutics
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100